Law360, New York (April 15, 2005, 12:00 AM ET) -- The U.S. Food and Drug Administration has granted Barr Laboratories a final approval for a generic version of Aventis Pharmaceuticals' blockbuster allergy medicine Allegra-D, the company said.
The move would give Barr the right to make a generic version of the 12-hour 60mg and 120 mg extended-release tablets if the company prevails in a patent challenge against the French drug maker.
Barr is the first applicant to file an abbreviated New Drug Application containing a paragraph IV patent challenge on the patents relating to the Allegra-D...
Barr Gets FDA Green Light For Allegra-D Amid Patent Dispute
To view the full article, take a free trial now.
